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Results: Dose of busulfan was adjusted in 25 patients (54%). 
Through levels 25 to 1244 ng/mL, peak levels 849–4586 ng/mL 
bearing AUC 2225 ng/mL.h–12,818 ng/mL.h were observed. The 
median total dose of infused drug was 17.52 mg/kg (10.7–22.9). 
All patients have engrafted, 33 (94%) patients after allogeneic 
HSCT have reached complete donor chimerism. Acute graft versus 
host disease grade III-IV manifested in 6 (17%), mucositis grade 
III-IV was seen in 28 (61%), and VOD was diagnosed in 8 (17%) 
patients. Defibrotide was administered in 15 patients (therapeuti-
cally in 9, as prophylaxis in 8). Neurotoxicity was documented 
in 2 patients. Relapse occurred in 6 (13 %) patients; 10 (22%) 
patients died, 5 due to toxicity before day 100 after HSTC, 1 child 
15 months after HSCT, 4 due to relapse. 32 children are alive/
well (70%).
Conclusion: Parenteral busulfan was used in full myeloablative dose 
and in combination with other drugs; therefore, toxicity rather than 
underexposure was our main concern. However, clear correlation 
between AUC and toxicity was not observed. Because of interindivid-
ual differences and changes in pharmacokinetics during the busulfan 
course, we strongly recommend intensive TDM.
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Introduction: Angiogenesis inhibitors have remarkably improved the 
outcome of patients with several types of cancer. One of the most 
reported side effects of angiogenesis inhibitors is hypertension. In a 
previous study, we showed that infusion of bevacizumab, an antibody 
directed against vascular endothelial growth factor (VEGF), acutely 
decreased endothelium-dependent vasodilation in healthy volunteers 
(A. Thijs et al Hypertension 2013;Epub ahead of print). Sunitinib, 
an inhibitor of tyrosine kinases including the VEGF-receptor, causes 
cardiovascular side effects similar to bevacizumab. We expected that 
antagonism of the VEGF receptor and subsequent endothelial dys-
function mediates these cardiovascular adverse events of sunitinib. 
Therefore, we hypothesized that sunitinib reduces endothelium-
dependent vasodilation before hypertension.
Patients (or Materials) and Methods: In patients with metastatic 
renal cell carcinoma before and 1 week after start of clinically 
indicated sunitinib (50 mg/d) the endothelium-dependent vasodi-
lator response to intra-arterial acetycholine (ACH, 0.5, 2.0, and 
8.0 µg/dL forearm volume/min) and the endothelium-independent 
vasodilator response to intra-arterial sodium nitroprusside (SNP, 
0.06, 0.2, and 0.6 µg/dL forearm volume/min) were assessed with 
venous occlusion plethysmography. Moreover, blood pressure was 
measured in supine position at the end of each experiment. For 
statistical analyses, the FBF ratio (FBF in experimental arm/FBF in 
control arm) was logarithmically transformed to obtain a Gaussian 
distribution. Results are expressed as percentage response from 
baseline (mean [SEM]).
Results: Ten male patients with a mean age of 55 years (range, 
24–68 years) were included. No significant changes in FBFresponses 
before and after start of sunitinib were observed (Table). Blood 
pressure (MAP) before was 101.9 (3.8) mm Hg and 106.1 (2.6) 
mm Hg after 1 week of treatment (not significant). After 2 weeks 
of treatment, the blood pressure had increased to 115.8 (4.9) mm 
Hg (P < 0.05).
Conclusion: One-week treatment with sunitinib did not specifically 
affect endothelium-dependent vasodilation before the development 
of hypertension.These observations indicate that bevacizumab and 
sunitinib differ with respect to their vascular actions in humans in 
vivo and suggest that other factors contribute to the development of 
hypertension in response to sunitinib rather than endothelial dys-
function.
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Introduction: Pancreatic cancer patients have an overall 5-year sur-
vival of < 5% worldwide, due to both late-stage diagnosis and lack of 
treatment options. Therefore, the development of novel chemothera-
peutic modalities based on a deeper understanding of the disease is 
essential for improving patient survival. We have recently developed 
Minnelide, a novel prodrug of the diterpene triepoxide, triptolide, as 
a novel chemotherapy against pancreatic cancer. Although Minnelide 
has shown great promise in preclinical studies using various animal 
models of pancreatic cancer, its mechanism of action remains unclear. 
NFkB activity and HSP70 expression are pro-survival pathways up-
regulated in pancreatic cancer. Previous studies from our group and 
others have shown that triptolide decreases NFkB activity. We have 
also shown that triptolide-mediated loss of HSP70 results in pancre-
atic cancer cell death. However, it is unclear if down-regulation of 
both HSP70 and NFkB are part of sequential or parallel pathways. 
We hypothesized that a triptolide-mediated decrease in NFkB activity 
results in down-regulation of HSPs, resulting in cell death.
Patients (or Materials) and Methods: Tumor volume evaluation: 
5 × 105 MIA PaCa-2, S2-VP10, S2-013, AsPC-1, or KPC (derived 
from KRasG12D; Tp53R172H; Pdx-1 Cre animals) pancreatic can-
cer cells were injected subcutaneously into animals and tumor volume 
measured 28 days postinoculation. RNA and Protein: RNA levels 
were assessed using real-time qPCR. Protein levels were evaluated by 
western blotting. NFkB activity: NFkB activity was measured using 
a p50 binding assay kit (Pierce).
Results: Using either KPC cell lines, known to mimic human pan-
creatic cancer progression, or human tumors, we show that the KPC 
cell line is the most aggressive of all cell lines tested in its ability to 
form tumors. The KPC cell line also possesses the highest NFkB activ-
ity of all cell lines tested, accentuating the importance of NFkB in 
pancreatic cancer. To evaluate the mechanism of action of Minnelide, 
we used 2 human tumor-derived pancreatic cancer cell lines: MIA 
PaCa-2, derived from a primary tumor, and S2-VP10, derived from 
a liver metastasis. In both of these cell lines, triptolide treatment 
decreases RNA and protein levels of p50 and p65, as well as NFkB 
Table. FBF ratio (% increase from baseline)
ACH 0.05 ACH 2.0 ACH 8.0 SNP 0.06 SNP 0.2 SNP 0.6
Before 
sunitinib
246 (100) 1098 
(765)
1412 
(737)
692 (357) 1184 
(552)
3703 
(2320)
After 
sunitinib
201 (76) 252 (72) 542 (144) 378 (158) 1078 
(614)
1746 
(665)
